Table 3.
Open in new tab

Hazard Ratios of Subtypes of Stroke by Different Levels of Body Mass Index at Baseline and During Follow-up Among Patients with Type 2 Diabetes

Body mass index, kg/m2P for trendEach 1 kg/m2 increase
18.5–24.925.0–29.930.0–34.935.0–39.9≥40.0
Hemorrhagic
Baseline
 No. of patients775618 59318 93311 64810 156
 No. of cases1182001156743
 Person-years25 21764 27167 70343 10137 621
 Hazard ratios (95% CI)
  Model 11.000.78 (0.62–0.98) 0.49 (0.37–0.63)0.50 (0.37–0.68)0.42 (0.29–0.61)<0.0010.958 (0.944–0.972)
  Model 21.000.79 (0.63–0.99)0.50 (0.38–0.65)0.50 (0.37–0.69)0.41 (0.28–0.59)<0.0010.957 (0.943–0.971)
Follow-up
 No. of patients800918 53818 92411 55610 059
 No. of cases1231981136643
 Person-years25 48564 13567 72142 82437 260
 Hazard ratios (95% CI)
  Model 11.000.75 (0.60–0.94)0.47 (0.36–0.60)0.48 (0.35–0.65)0.41 (0.29–0.59)<0.0010.957 (0.943–0.971)
  Model 21.000.77 (0.61–0.96)0.47 (0.36–0.62)0.48 (0.35–0.66)0.40 (0.28–0.58)<0.0010.956 (0.942–0.970)
Ischemic
Baseline
 No. of patients775618 59318 93311 64810 156
 No. of cases1328270323741195775
 Person-years26 94168 14971 36244 95338 865
 Hazard ratios (95% CI)
  Model 11.000.96 (0.90–1.03)0.94 (0.87–1.00)0.83 (0.77–0.90)0.71 (0.65–0.78)<0.0010.986 (0.983–0.990)
  Model 21.000.93 (0.87–0.99)0.88 (0.82–0.94)0.77 (0.71–0.83)0.65 (0.59–0.71)<0.0010.981 (0.978–0.985)
Follow-up
 No. of patients800918 53818 92411 55610 059
 No. of cases1357270623681175769
 Person-years27 27567 98371 38444 64938 488
 Hazard ratios (95% CI)
  Model 11.000.96 (0.90–1.03)0.93 (0.87–0.99)0.82 (0.76–0.89)0.71 (0.65–0.78)<0.0010.986 (0.983–0.989)
  Model 21.000.93 (0.87–0.99)0.88 (0.82–0.94)0.76 (0.70–0.82)0.65 (0.59–0.71)<0.0010.981 (0.978–0.985)
Body mass index, kg/m2P for trendEach 1 kg/m2 increase
18.5–24.925.0–29.930.0–34.935.0–39.9≥40.0
Hemorrhagic
Baseline
 No. of patients775618 59318 93311 64810 156
 No. of cases1182001156743
 Person-years25 21764 27167 70343 10137 621
 Hazard ratios (95% CI)
  Model 11.000.78 (0.62–0.98) 0.49 (0.37–0.63)0.50 (0.37–0.68)0.42 (0.29–0.61)<0.0010.958 (0.944–0.972)
  Model 21.000.79 (0.63–0.99)0.50 (0.38–0.65)0.50 (0.37–0.69)0.41 (0.28–0.59)<0.0010.957 (0.943–0.971)
Follow-up
 No. of patients800918 53818 92411 55610 059
 No. of cases1231981136643
 Person-years25 48564 13567 72142 82437 260
 Hazard ratios (95% CI)
  Model 11.000.75 (0.60–0.94)0.47 (0.36–0.60)0.48 (0.35–0.65)0.41 (0.29–0.59)<0.0010.957 (0.943–0.971)
  Model 21.000.77 (0.61–0.96)0.47 (0.36–0.62)0.48 (0.35–0.66)0.40 (0.28–0.58)<0.0010.956 (0.942–0.970)
Ischemic
Baseline
 No. of patients775618 59318 93311 64810 156
 No. of cases1328270323741195775
 Person-years26 94168 14971 36244 95338 865
 Hazard ratios (95% CI)
  Model 11.000.96 (0.90–1.03)0.94 (0.87–1.00)0.83 (0.77–0.90)0.71 (0.65–0.78)<0.0010.986 (0.983–0.990)
  Model 21.000.93 (0.87–0.99)0.88 (0.82–0.94)0.77 (0.71–0.83)0.65 (0.59–0.71)<0.0010.981 (0.978–0.985)
Follow-up
 No. of patients800918 53818 92411 55610 059
 No. of cases1357270623681175769
 Person-years27 27567 98371 38444 64938 488
 Hazard ratios (95% CI)
  Model 11.000.96 (0.90–1.03)0.93 (0.87–0.99)0.82 (0.76–0.89)0.71 (0.65–0.78)<0.0010.986 (0.983–0.989)
  Model 21.000.93 (0.87–0.99)0.88 (0.82–0.94)0.76 (0.70–0.82)0.65 (0.59–0.71)<0.0010.981 (0.978–0.985)

Model 1 adjusted for age, sex and race; Model 2 is additionally adjusted for insurance, smoking, systolic blood pressure, HbA1c, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, eGFR, use of antihypertensive drugs, use of thiazolidinediones, use of lipid-lowering agents, use of antiplatelet agents, and use of anticoagulant agents.

Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1C.

Table 3.
Open in new tab

Hazard Ratios of Subtypes of Stroke by Different Levels of Body Mass Index at Baseline and During Follow-up Among Patients with Type 2 Diabetes

Body mass index, kg/m2P for trendEach 1 kg/m2 increase
18.5–24.925.0–29.930.0–34.935.0–39.9≥40.0
Hemorrhagic
Baseline
 No. of patients775618 59318 93311 64810 156
 No. of cases1182001156743
 Person-years25 21764 27167 70343 10137 621
 Hazard ratios (95% CI)
  Model 11.000.78 (0.62–0.98) 0.49 (0.37–0.63)0.50 (0.37–0.68)0.42 (0.29–0.61)<0.0010.958 (0.944–0.972)
  Model 21.000.79 (0.63–0.99)0.50 (0.38–0.65)0.50 (0.37–0.69)0.41 (0.28–0.59)<0.0010.957 (0.943–0.971)
Follow-up
 No. of patients800918 53818 92411 55610 059
 No. of cases1231981136643
 Person-years25 48564 13567 72142 82437 260
 Hazard ratios (95% CI)
  Model 11.000.75 (0.60–0.94)0.47 (0.36–0.60)0.48 (0.35–0.65)0.41 (0.29–0.59)<0.0010.957 (0.943–0.971)
  Model 21.000.77 (0.61–0.96)0.47 (0.36–0.62)0.48 (0.35–0.66)0.40 (0.28–0.58)<0.0010.956 (0.942–0.970)
Ischemic
Baseline
 No. of patients775618 59318 93311 64810 156
 No. of cases1328270323741195775
 Person-years26 94168 14971 36244 95338 865
 Hazard ratios (95% CI)
  Model 11.000.96 (0.90–1.03)0.94 (0.87–1.00)0.83 (0.77–0.90)0.71 (0.65–0.78)<0.0010.986 (0.983–0.990)
  Model 21.000.93 (0.87–0.99)0.88 (0.82–0.94)0.77 (0.71–0.83)0.65 (0.59–0.71)<0.0010.981 (0.978–0.985)
Follow-up
 No. of patients800918 53818 92411 55610 059
 No. of cases1357270623681175769
 Person-years27 27567 98371 38444 64938 488
 Hazard ratios (95% CI)
  Model 11.000.96 (0.90–1.03)0.93 (0.87–0.99)0.82 (0.76–0.89)0.71 (0.65–0.78)<0.0010.986 (0.983–0.989)
  Model 21.000.93 (0.87–0.99)0.88 (0.82–0.94)0.76 (0.70–0.82)0.65 (0.59–0.71)<0.0010.981 (0.978–0.985)
Body mass index, kg/m2P for trendEach 1 kg/m2 increase
18.5–24.925.0–29.930.0–34.935.0–39.9≥40.0
Hemorrhagic
Baseline
 No. of patients775618 59318 93311 64810 156
 No. of cases1182001156743
 Person-years25 21764 27167 70343 10137 621
 Hazard ratios (95% CI)
  Model 11.000.78 (0.62–0.98) 0.49 (0.37–0.63)0.50 (0.37–0.68)0.42 (0.29–0.61)<0.0010.958 (0.944–0.972)
  Model 21.000.79 (0.63–0.99)0.50 (0.38–0.65)0.50 (0.37–0.69)0.41 (0.28–0.59)<0.0010.957 (0.943–0.971)
Follow-up
 No. of patients800918 53818 92411 55610 059
 No. of cases1231981136643
 Person-years25 48564 13567 72142 82437 260
 Hazard ratios (95% CI)
  Model 11.000.75 (0.60–0.94)0.47 (0.36–0.60)0.48 (0.35–0.65)0.41 (0.29–0.59)<0.0010.957 (0.943–0.971)
  Model 21.000.77 (0.61–0.96)0.47 (0.36–0.62)0.48 (0.35–0.66)0.40 (0.28–0.58)<0.0010.956 (0.942–0.970)
Ischemic
Baseline
 No. of patients775618 59318 93311 64810 156
 No. of cases1328270323741195775
 Person-years26 94168 14971 36244 95338 865
 Hazard ratios (95% CI)
  Model 11.000.96 (0.90–1.03)0.94 (0.87–1.00)0.83 (0.77–0.90)0.71 (0.65–0.78)<0.0010.986 (0.983–0.990)
  Model 21.000.93 (0.87–0.99)0.88 (0.82–0.94)0.77 (0.71–0.83)0.65 (0.59–0.71)<0.0010.981 (0.978–0.985)
Follow-up
 No. of patients800918 53818 92411 55610 059
 No. of cases1357270623681175769
 Person-years27 27567 98371 38444 64938 488
 Hazard ratios (95% CI)
  Model 11.000.96 (0.90–1.03)0.93 (0.87–0.99)0.82 (0.76–0.89)0.71 (0.65–0.78)<0.0010.986 (0.983–0.989)
  Model 21.000.93 (0.87–0.99)0.88 (0.82–0.94)0.76 (0.70–0.82)0.65 (0.59–0.71)<0.0010.981 (0.978–0.985)

Model 1 adjusted for age, sex and race; Model 2 is additionally adjusted for insurance, smoking, systolic blood pressure, HbA1c, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, eGFR, use of antihypertensive drugs, use of thiazolidinediones, use of lipid-lowering agents, use of antiplatelet agents, and use of anticoagulant agents.

Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1C.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close